Type 2 diabetes
Conditions
Interventions
8 weeks administration of Empagliflozin 10mg q.d.
Standard care
Sponsors
Tokyo Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: HbA1c >= 7.0% and HbA1c < 10%
Exclusion criteria
Exclusion criteria: 1. Diagnosed as diabetes within the last 6 months 2. Taking SGLT2 inhibitors 3. Taking diuretics 4. Pituitary dysfunction or adrenal insufficiency 5. Excessive alcohol intake 8. eGFR < 30mL / min / 1.73m2(MDRD) 9. AST >= 165 or ALT >= 210 10. Serum C-peptide < 0.5ng / mL 11. History of severe hypoglycemia within the last 3 months 12. Systolic blood pressure >= 200 mmHg or diastolic blood pressure >=120 mmHg 13. Secondary hypertension 14. Vitreous hemorrhage, unstable proliferative diabetic retinopathy 15. Severe diabetic neuropathy 16. Positive anti-GAD antibody 17. During pregnancy 18. Chronic atrial fibrillation 19. History of pyelonephritis 20. Claustrophobia, pacemaker, the metal in the body, weighing 150 kg or more 21. Unable to hold the breath longer than 20 seconds
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intramyocardial lipid deposition measured by magnetic resonance spectroscopy (MRS): Time Frame of 8 weeks | — |
Countries
Japan
Contacts
Public ContactKazuo Hara
Tokyo Medical University Division of Diabetes, Endocrinology and Metabolism
Outcome results
None listed